From the Research
For primary facial hyperhidrosis, topical glycopyrrolate 2% is the most effective and recommended treatment, with a faster onset of action and comparable results to Botulinum toxin A, as shown in the most recent study 1. The treatment of primary facial hyperhidrosis aims to reduce excessive sweating and improve the patient's quality of life.
- The most recent study 1 compared the efficacy and safety of topical 2% glycopyrrolate and intradermal Botulinum toxin A injection in 24 patients with primary facial hyperhidrosis.
- The results showed that both treatments had a complete response in 75% of cases, with a longer duration of action in the Botulinum toxin group, but topical glycopyrrolate had a faster onset of action.
- The Hyperhidrosis Disease Severity Scale and Dermatology Life Quality Index (DLQI) showed statistically significant improvement after treatment with both modalities.
- Topical glycopyrrolate 2% is a recommended treatment option for primary facial hyperhidrosis, with a faster onset of action and fewer systemic side effects compared to oral anticholinergic medications.
- The dosage of topical glycopyrrolate 2% can be applied as needed, with a recommended frequency of application to achieve optimal results.
- Other treatment options, such as oral anticholinergic medications, including glycopyrrolate and oxybutynin, may be considered if topical treatments are not effective or tolerated, as suggested in earlier studies 2, 3, 4, 5.